|
Jun 25
|
Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal
|
|
Jun 25
|
FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP
|
|
Jun 25
|
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
|
|
Jun 25
|
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
|
|
Jun 25
|
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
|
|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Apr 10
|
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
|
|
Apr 10
|
PatientView Ranks Gilead "Best" at ESG
|
|
Apr 9
|
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
|
|
Apr 9
|
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
|
|
Apr 9
|
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
|
|
Apr 9
|
2 Top Dividend Stocks That Could Set You Up for Life
|
|
Apr 8
|
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections
|
|
Apr 7
|
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
|
|
Feb 26
|
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant
|
|
Feb 26
|
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
|
|
Feb 25
|
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
|
|
Feb 25
|
Morgan Stanley sees FDA approval of GILD's Lenacapavir
|
|
Feb 25
|
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
|
|
Feb 25
|
Gilead’s lenacapavir applications for HIV gain EMA validation
|